相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Prognostic factors for outcome in patients with refractory and relapsed acute lymphocytic leukemia treated with inotuzumab ozogamicin, a CD22 monoclonal antibody
Elias Jabbour et al.
AMERICAN JOURNAL OF HEMATOLOGY (2015)
T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial
Daniel W. Lee et al.
LANCET (2015)
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
Max S. Topp et al.
LANCET ONCOLOGY (2015)
UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia
Adele K. Fielding et al.
BLOOD (2014)
Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial
Dieter Hoelzer et al.
BLOOD (2014)
Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: cancer and Leukemia Group B study 10002
David A. Rizzieri et al.
BRITISH JOURNAL OF HAEMATOLOGY (2014)
Augmented Berlin-Frankfurt-Munster Therapy in Adolescents and Young Adults (AYAs) With Acute Lymphoblastic Leukemia (ALL)
Michael E. Rytting et al.
CANCER (2014)
Acute lymphoblastic leukemia with low hypodiploid/near triploid karyotype is a specific clinical entity and exhibits a very high TP53 mutation frequency of 93%
Verena Muehlbacher et al.
GENES CHROMOSOMES & CANCER (2014)
Outcomes of Children With BCR-ABL1-Like Acute Lymphoblastic Leukemia Treated With Risk-Directed Therapy Based on the Levels of Minimal Residual Disease
Kathryn G. Roberts et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Phase II Trial of the Anti-CD19 Bispecific T Cell-Engager Blinatumomab Shows Hematologic and Molecular Remissions in Patients With Relapsed or Refractory B-Precursor Acute Lymphoblastic Leukemia
Max S. Topp et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Treatment of High-Risk Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia in Adolescents and Adults According to Early Cytologic Response and Minimal Residual Disease After Consolidation Assessed by Flow Cytometry: Final Results of the PETHEMA ALL-AR-03 Trial
Josep-Maria Ribera et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
The combination of hyper-CVAD plus nelarabine as frontline therapy in adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma: MD Anderson Cancer Center experience
P. Jain et al.
LEUKEMIA (2014)
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Shannon L. Maude et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia
K. G. Roberts et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
Marco L. Davila et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Long-Term Follow-Up of the Imatinib GRAAPH-2003 Study in Newly Diagnosed Patients with De Novo Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A GRAALL Study
Aline Tanguy-Schmidt et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2013)
Whole-exome sequencing in adult ETP-ALL reveals a high rate of DNMT3A mutations
Martin Neumann et al.
BLOOD (2013)
Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy
Farhad Ravandi et al.
BLOOD (2013)
Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia
Hagop Kantarjian et al.
CANCER (2013)
Feasibility of Allografting in Patients with Advanced Acute Lymphoblastic Leukemia After Salvage Therapy With Inotuzumab Ozogamicin
Partow Kebriaei et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2013)
Acute lymphoblastic leukaemia
Hiroto Inaba et al.
LANCET (2013)
The genomic landscape of hypodiploid acute lymphoblastic leukemia
Linda Holmfeldt et al.
NATURE GENETICS (2013)
Low-Intensity Therapy in Adults with Burkitt's Lymphoma
Kieron Dunleavy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Chimeric Antigen Receptor-Modified T Cells for Acute Lymphoid Leukemia
Stephan A. Grupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)
Hagop M. Kantarjian et al.
BLOOD (2012)
Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation
Nicola Goekbuget et al.
BLOOD (2012)
Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL
Max S. Topp et al.
BLOOD (2012)
Pediatric acute lymphoblastic leukemia: where are we going and how do we get there?
Ching-Hon Pui et al.
BLOOD (2012)
Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies
Nicola Goekbuget et al.
BLOOD (2012)
Chemoimmunotherapy in acute lymphoblastic leukemia
Dieter Hoelzer et al.
BLOOD REVIEWS (2012)
Outcomes in older adults with acute lymphoblastic leukaemia (ALL): results from the international MRC UKALL XII/ECOG2993 trial
Jonathan I. Sive et al.
BRITISH JOURNAL OF HAEMATOLOGY (2012)
Cancer Statistics, 2012
Rebecca Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2012)
Genetic Alterations Activating Kinase and Cytokine Receptor Signaling in High-Risk Acute Lymphoblastic Leukemia
Kathryn G. Roberts et al.
CANCER CELL (2012)
Inotuzumab ozogamicin in the treatment of B-cell acute lymphoblastic leukemia
Xavier Thomas
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2012)
Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study
Hagop Kantarjian et al.
LANCET ONCOLOGY (2012)
The genetic basis of early T-cell precursor acute lymphoblastic leukaemia
Jinghui Zhang et al.
NATURE (2012)
Ponatinib in Refractory Philadelphia Chromosome-Positive Leukemias
Jorge E. Cortes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Blinatumomab: A historical perspective
Dirk Nagorsen et al.
PHARMACOLOGY & THERAPEUTICS (2012)
Targeted Therapy With the T-Cell-Engaging Antibody Blinatumomab of Chemotherapy-Refractory Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Patients Results in High Response Rate and Prolonged Leukemia-Free Survival
Max S. Topp et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Chimeric Antigen Receptor-Modified T Cells in Chronic Lymphoid Leukemia
David L. Porter et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group
Libi Hertzberg et al.
BLOOD (2010)
Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia
Richard C. Harvey et al.
BLOOD (2010)
First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia
Farhad Ravandi et al.
BLOOD (2010)
Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study
Valentino Conter et al.
BLOOD (2010)
Safety, Pharmacokinetics, and Preliminary Clinical Activity of Inotuzumab Ozogamicin, a Novel Immunoconjugate for the Treatment of B-Cell Non-Hodgkin's Lymphoma: Results of a Phase I Study
Anjali Advani et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Chemotherapy-Phased Imatinib Pulses Improve Long-Term Outcome of Adult Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Northern Italy Leukemia Group Protocol 09/00
Renato Bassan et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Chemoimmunotherapy With a Modified Hyper-CVAD and Rituximab Regimen Improves Outcome in De Novo Philadelphia Chromosome-Negative Precursor B-Lineage Acute Lymphoblastic Leukemia
Deborah A. Thomas et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia
Giuseppe Saglio et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia
Akinori Yoda et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Minimal Residual Disease in Acute Lymphoblastic Leukemia
Dario Campana
HEMATOLOGY-AMERICAN SOCIETY HEMATOLOGY EDUCATION PROGRAM (2010)
Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL)
Renato Bassan et al.
BLOOD (2009)
Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia
Lisa J. Russell et al.
BLOOD (2009)
AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance
Thomas O'Hare et al.
CANCER CELL (2009)
Nelarabine for the Treatment of Patients with Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
Daniel J. DeAngelo
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2009)
Pediatric-Inspired Therapy in Adults With Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: The GRAALL-2003 Study
Francoise Huguet et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia
Elaine Coustan-Smith et al.
LANCET ONCOLOGY (2009)
A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study
Monique L. Den Boer et al.
LANCET ONCOLOGY (2009)
Prognostic significance of minimal residual disease in infants with acute lymphoblastic leukemia treated within the Interfant-99 protocol
V. H. J. Van der Velden et al.
LEUKEMIA (2009)
Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia
Charles G. Mullighan et al.
NATURE GENETICS (2009)
Deletion of IKZF1 and Prognosis in Acute Lymphoblastic Leukemia.
Charles G. Mullighan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Treating Childhood Acute Lymphoblastic Leukemia without Cranial Irradiation
Ching-Hon Pui et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies
Wendy Stock et al.
BLOOD (2008)
Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study
Michael J. Borowitz et al.
BLOOD (2008)
Results of the Hyperfractionated Cyclophosphamide, Vincristine, Doxorubicin, and Dexamethasone Regimen in Elderly Patients With Acute Lymphocytic Leukemia
Susan O'Brien et al.
CANCER (2008)
In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993)
Anthony H. Goldstone et al.
BLOOD (2008)
Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial
E. Tavernier et al.
LEUKEMIA (2007)
Molecular relapse in adult standard-risk ALL patients detected by prospective MRD monitoring during and after maintenance treatment:: data from the GMALL 06/99 and 07/03 trials
Thorsten Raff et al.
BLOOD (2007)
Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL)
Barbara Wassmann et al.
BLOOD (2006)
Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia
DA Thomas et al.
CANCER (2006)
Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia
M Brüggemann et al.
BLOOD (2006)
Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia
YG Hu et al.
NATURE GENETICS (2004)
Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia
H Kantarjian et al.
CANCER (2004)
Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia -: results of the prospective multicenter LALA-94 trial
H Dombret et al.
BLOOD (2002)
分享论文
